Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent cetuximab, irinotecan, oxaliplatin and UFT in first-line metastatic colorectal cancer
2007-002053-24Phase 2Terminated
- Sponsor
- The Christie
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal adenocarcinoma, sponsored by The Christie. Primary endpoint: Objective response rate by RECIST after 8 weeks. Started Oct 2007; status: terminated.
02
Drugs
cetuximab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2007-002053-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002053-24.